229 related articles for article (PubMed ID: 34624138)
21. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome.
Baillargeon JP; Diamanti-Kandarakis E; Ostlund RE; Apridonidze T; Iuorno MJ; Nestler JE
Diabetes Care; 2006 Feb; 29(2):300-5. PubMed ID: 16443877
[TBL] [Abstract][Full Text] [Related]
22. Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction.
Galletta M; Grasso S; Vaiarelli A; Roseff SJ
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1212-4. PubMed ID: 22165685
[TBL] [Abstract][Full Text] [Related]
23. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols.
Sortino MA; Salomone S; Carruba MO; Drago F
Front Pharmacol; 2017; 8():341. PubMed ID: 28642705
[TBL] [Abstract][Full Text] [Related]
24. Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond.
Facchinetti F; Appetecchia M; Aragona C; Bevilacqua A; Bezerra Espinola MS; Bizzarri M; D'Anna R; Dewailly D; Diamanti-Kandarakis E; Hernández Marín I; Kamenov ZA; Kandaraki E; Laganà AS; Monastra G; Montanino Oliva M; Nestler JE; Orio F; Ozay AC; Papalou O; Pkhaladze L; Porcaro G; Prapas N; Soulage CO; Stringaro A; Wdowiak A; Unfer V
Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):255-274. PubMed ID: 32129111
[No Abstract] [Full Text] [Related]
25. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.
Galazis N; Galazi M; Atiomo W
Gynecol Endocrinol; 2011 Apr; 27(4):256-62. PubMed ID: 21142777
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.
Laganà AS; Barbaro L; Pizzo A
Arch Gynecol Obstet; 2015 May; 291(5):1181-6. PubMed ID: 25416201
[TBL] [Abstract][Full Text] [Related]
27. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial.
Mendoza N; Galan MI; Molina C; Mendoza-Tesarik R; Conde C; Mazheika M; Diaz-Ropero MP; Fonolla J; Tesarik J; Olivares M
Gynecol Endocrinol; 2020 May; 36(5):398-401. PubMed ID: 31657275
[TBL] [Abstract][Full Text] [Related]
28. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.
Colazingari S; Treglia M; Najjar R; Bevilacqua A
Arch Gynecol Obstet; 2013 Dec; 288(6):1405-11. PubMed ID: 23708322
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial.
Mendoza N; Diaz-Ropero MP; Aragon M; Maldonado V; Llaneza P; Lorente J; Mendoza-Tesarik R; Maldonado-Lobon J; Olivares M; Fonolla J
Gynecol Endocrinol; 2019 Aug; 35(8):695-700. PubMed ID: 30880505
[TBL] [Abstract][Full Text] [Related]
30. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women.
Benelli E; Del Ghianda S; Di Cosmo C; Tonacchera M
Int J Endocrinol; 2016; 2016():3204083. PubMed ID: 27493664
[TBL] [Abstract][Full Text] [Related]
31. Potential role of d-
Simic D; Nikolic Turnic T; Dimitrijevic A; Zivadinovic A; Milosevic-Stevanovic J; Djuric D; Zivkovic V; Jakovljevic V
Can J Physiol Pharmacol; 2022 Jul; 100(7):629-636. PubMed ID: 35413205
[TBL] [Abstract][Full Text] [Related]
32. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Croze ML; Soulage CO
Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
[TBL] [Abstract][Full Text] [Related]
33. Inositols in the ovaries: activities and potential therapeutic applications.
Laganà AS; Forte G; Bizzarri M; Kamenov ZA; Bianco B; Kaya C; Gitas G; Alkatout I; Terzic M; Unfer V
Expert Opin Drug Metab Toxicol; 2022 Feb; 18(2):123-133. PubMed ID: 35472446
[TBL] [Abstract][Full Text] [Related]
34. Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS.
Unfer V; Dinicola S; Laganà AS; Bizzarri M
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998310
[TBL] [Abstract][Full Text] [Related]
35. Inositols in PCOS.
Kamenov Z; Gateva A
Molecules; 2020 Nov; 25(23):. PubMed ID: 33260918
[TBL] [Abstract][Full Text] [Related]
36. Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model.
Zhang Y; Li C; Zhang W; Zheng X; Chen X
J Med Food; 2020 Apr; 23(4):375-387. PubMed ID: 32045334
[TBL] [Abstract][Full Text] [Related]
37. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Nestler JE; Jakubowicz DJ; Reamer P; Gunn RD; Allan G
N Engl J Med; 1999 Apr; 340(17):1314-20. PubMed ID: 10219066
[TBL] [Abstract][Full Text] [Related]
38. Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity.
Villeneuve MC; Ostlund RE; Baillargeon JP
Metabolism; 2009 Jan; 58(1):62-8. PubMed ID: 19059532
[TBL] [Abstract][Full Text] [Related]
39. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
[TBL] [Abstract][Full Text] [Related]
40. A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome.
Nazirudeen R; Sridhar S; Priyanka R; Sumathi B; Natarajan V; Subbiah E; Raghavan KS; Sangumani J
Clin Endocrinol (Oxf); 2023 Aug; 99(2):198-205. PubMed ID: 37265016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
